MedTrace Logo

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

NCT04358549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-03-29

Study results available
· View outcomes & findings →

Summary

To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.

Conditions

Interventions

DRUG

Favipiravir

Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets

OTHER

Standard of Care

Standard of Care for individual study site as determined by each hospital's protocol

Sponsors & Collaborators

  • Fujifilm Pharmaceuticals U.S.A., Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2020-09-30
Completion
2020-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04358549 on ClinicalTrials.gov